Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

JAMA

Volumn 282, Issue 20, 1999, Pages 1929-1933

  Langman, Michael J ^a   Jensen, Dennis M ^c   Watson, Douglas J ^b   Harper, Scan E ^b   Zhao, Peng Liang ^b   Quan, Hui ^b   Bolognese, James A ^b   Simon, Thomas J ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Department of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NABUMETONE; PARACETAMOL; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM HEMORRHAGE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DUODENUM PERFORATION; ENZYME INHIBITION; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PERFORATION; UPPER GASTROINTESTINAL TRACT;

EID: 0033601079     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.20.1929     Document Type: Article

References (27)

1. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J Clin Invest. 1994;93:1095-1101.
2. Hla T, Neilson K. Human cydooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89:7384-7388.
3. Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthetase in cultured epithelial cells. J Biol Chem. 1992; 267:21438-21445.
4. Sirois J, Simmons DL, Richards JS. Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthetase in rat preovulatory follicles. J Biol Chem. 1992;267: 11586-11592.
5. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders Co; 1998:343-357.
6. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem. 1993; 268:6610-6614.
7. Fosslien E. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci. 1998;28:67-81.
8. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993;90:11693-11697.
9. Griffin MR, Ray WA, Schaffner W. Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988;109:359-363.
10. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343: 1075-1078.
11. Somerville K, Faulkner G, Langman MJ. Nonsteroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet. 1986;1:462-464.
12. Singh G. Recent considerations in nonsteroidal antiinflammatory drug gastropathy [review]. Am J Med. 1998;105(suppl 1B):31S-38S.
13. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336-347.
14. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res. 1996; 45:68-74.
15. Depre M, Ehrich E, De Lepeleire I, et al. Demonstration of specific COX-2 inhibition by MK-966 (vioxx) in humans with supratherapeutic doses [abstract]. Rheum Europe. 1998;27(suppl 2):196.
16. Cryer B, Gottesdiener K, Gertz B, et al. Effects of a novel cyclooxygenase (COX)-2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans [abstract]. Am J Gastroenterol. 1996;91:1907.
17. Bjarnason I, Sigthorsson G, Crane R, et al. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. does not increase intestinal permeability [abstract]. Am J Gastroenterol. 1998;93:1670.
18. Hunt R, Bowen B, James C, et al. COX-2 specific inhibition with MK-096625 or 50 mg Q.D. over 4 weeks does not increase fecal blood loss [abstract]. Am J Gastroenterol. 1998;93:1671.
19. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg Q.D.) is associated with less gastroduodenal damage than aspirin (ASA) 650 mg Q.I.D or ibuprofen (IBU) 800 mg T.I.D. [abstract]. Gastroenterology. 1998;112:A194.
20. Laine L, Hawkey C, Harper S, et al. Effect of the COX-2 specific inhibrtor(C-2SI) rofecoxib on ulcer formation [abstract]. Gastroenterology. 1999;116:A229.
21. Barner A. Review of clinical trials and benefit/ risk ratio of meloxicam. Scam J Rheumatol. 1996;25 (suppl 102):29-37.
22. US package circular: Cataflam/Voltaren/Votaren X-R. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 1999:2001-2004.
23. US package circular: Motrin. In: Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 1999: 1674-1678.
24. Breslow N, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Stat. 1974;2:437-453.
25. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241-249.
26. Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial [abstract]. Arthritis Rheum. 1998;41:S196.
27. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial [abstract]. Arthritis Rheum. 1998;41:S196.